Hapten-carrier conjugates for treating and preventing nicotine addiction
AssigneeNabi
InventorsSofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
Life of this patent
Estimating the term…
Loading patent…
AssigneeNabi
InventorsSofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
Estimating the term…
Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.
An antibody produced in response to a hapten-carrier conjugate of the following formula:
An antibody produced in response to the hapren carrier conjugate of the following formula:
A process for producing an antibody, comprising immunizing a host mammal with the hapten-carrier conjugate of the following formula:
A process for producing an antibody, comprising immunizing a host mammal with the hapten-carrier conjugate of the following formula:
Dependencies are inferred from the claim text.